Who
Ramiro Ribeiro
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, EyePoint.
In numbers
- Trades disclosed
- 50
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $1.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Mar 2024
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | $20K2,437 at $8.26 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | $20K2,438 at $8.26 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Sold | $37K2,437 at $15.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,437 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,438 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Sold | $37K2,438 at $15.02 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,437 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,438 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | $20K2,437 at $8.26 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | $20K2,438 at $8.26 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Sold | $37K2,437 at $15.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Sold | $37K2,438 at $15.02 | filing |
| 17 Apr 2026filed 20 Apr 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | $20K2,437 at $8.26 | filing |
| 17 Apr 2026filed 20 Apr 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Sold | $37K2,437 at $15.00 | filing |
| 17 Apr 2026filed 20 Apr 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,437 at $0.00 | filing |
| 17 Apr 2026filed 20 Apr 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,437 at $0.00 | filing |
| 17 Apr 2026filed 20 Apr 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | $20K2,437 at $8.26 | filing |
| 17 Apr 2026filed 20 Apr 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Sold | $37K2,437 at $15.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | $20K2,438 at $8.26 | filing |
| 4 Mar 2026filed 5 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Sold | $44K2,438 at $17.87 | filing |
News
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Jefferies Financial Group to "Hold"EYPT · tickerreport.com · 19 Oct 2026Critical Review: Eyepoint Pharmaceuticals (NASDAQ:EYPT) and GSK (NYSE:GSK)EYPT · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Ramiro Ribeiro; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.